Trial Profile
Japan Morning Surge-Total Organ Protection: JMS-TOP Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Sep 2018
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Hypertension
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms J-TOP
- 10 Aug 2010 Status changed from active, no longer recruiting to completed.
- 21 Jun 2010 Results presented at the 20th European Meeting on Hypertension.
- 16 Apr 2010 Results have been published in the Journal of Hypertension.